You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameZiprasidone
Accession NumberDB00246  (APRD00540)
TypeSmall Molecule
GroupsApproved
DescriptionZiprasidone (marketed as Geodon, Zeldox) was the fifth atypical antipsychotic to gain FDA approval (February 2001). Ziprasidone is Food and Drug Administration (FDA) approved for the treatment of schizophrenia, and the intramuscular injection form of ziprasidone is approved for acute agitation in schizophrenic patients. Ziprasidone has also received approval for acute treatment of mania associated with bipolar disorder. [Wikipedia]
Structure
Thumb
Synonyms
Ziprasidona
Ziprasidone
Ziprasidonum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Gd-ziprasidoneCapsule80 mgOralGenmed A Division Of Pfizer Canada IncNot applicableNot applicableCanada
Gd-ziprasidoneCapsule20 mgOralGenmed A Division Of Pfizer Canada IncNot applicableNot applicableCanada
Gd-ziprasidoneCapsule40 mgOralGenmed A Division Of Pfizer Canada IncNot applicableNot applicableCanada
Gd-ziprasidoneCapsule60 mgOralGenmed A Division Of Pfizer Canada IncNot applicableNot applicableCanada
GeodonCapsule20 mg/1OralREMEDYREPACK INC.2010-12-20Not applicableUs
GeodonInjection, powder, lyophilized, for solution20 mg/mLIntramuscularCardinal Health2003-12-23Not applicableUs
GeodonCapsule60 mg/1OralRoerig2013-11-01Not applicableUs
GeodonCapsule20 mg/1OralSTAT Rx USA LLC2001-02-05Not applicableUs
GeodonInjection, powder, lyophilized, for solution20 mg/mLIntramuscularTYA Pharmaceuticals2003-12-23Not applicableUs
GeodonCapsule40 mg/1OralRoerig2001-02-05Not applicableUs
GeodonCapsule60 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-27Not applicableUs
GeodonCapsule80 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
GeodonCapsule80 mg/1OralRebel Distributors Corp2001-02-05Not applicableUs
GeodonCapsule80 mg/1OralRoerig2013-11-01Not applicableUs
GeodonCapsule60 mg/1OralREMEDYREPACK INC.2010-12-20Not applicableUs
GeodonCapsule40 mg/1OralCardinal Health2001-02-05Not applicableUs
GeodonCapsule20 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
GeodonCapsule20 mg/1OralRebel Distributors Corp2001-02-05Not applicableUs
GeodonCapsule60 mg/1OralRoerig2001-02-05Not applicableUs
GeodonCapsule20 mg/1OralUnit Dose Services2001-02-05Not applicableUs
GeodonCapsule20 mg/1OralCardinal Health2001-02-05Not applicableUs
GeodonCapsule20 mg/1OralRoerig2013-11-01Not applicableUs
GeodonCapsule40 mg/1OralREMEDYREPACK INC.2010-12-20Not applicableUs
GeodonCapsule60 mg/1OralCardinal Health2001-02-05Not applicableUs
GeodonInjection, powder, lyophilized, for solution20 mg/mLIntramuscularRoerig2003-12-23Not applicableUs
GeodonCapsule80 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2001-02-05Not applicableUs
GeodonCapsule40 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
GeodonCapsule40 mg/1OralRebel Distributors Corp2001-02-05Not applicableUs
GeodonCapsule80 mg/1OralRoerig2001-02-05Not applicableUs
GeodonCapsule80 mg/1OralCardinal Health2001-02-05Not applicableUs
GeodonCapsule40 mg/1OralRoerig2013-11-01Not applicableUs
GeodonCapsule80 mg/1OralREMEDYREPACK INC.2010-12-20Not applicableUs
GeodonInjection, powder, lyophilized, for solution20 mg/mLIntramuscularREMEDYREPACK INC.2015-02-13Not applicableUs
GeodonCapsule20 mg/1OralRoerig2001-02-05Not applicableUs
GeodonCapsule20 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-11-05Not applicableUs
GeodonCapsule60 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
GeodonCapsule60 mg/1OralRebel Distributors Corp2001-02-05Not applicableUs
ZeldoxCapsule80 mgOralPfizer Canada Inc2008-01-04Not applicableCanada
ZeldoxCapsule20.0 mgOralPfizer Canada Inc2008-01-04Not applicableCanada
ZeldoxCapsule40 mgOralPfizer Canada Inc2008-01-04Not applicableCanada
ZeldoxCapsule60 mgOralPfizer Canada Inc2008-01-04Not applicableCanada
ZiprasidoneCapsule40 mg/1OralGreenstone LLC2001-02-05Not applicableUs
ZiprasidoneCapsule40 mg/1OralREMEDYREPACK INC.2013-05-02Not applicableUs
ZiprasidoneCapsule60 mg/1OralGreenstone LLC2001-02-05Not applicableUs
ZiprasidoneCapsule80 mg/1OralGreenstone LLC2001-02-05Not applicableUs
ZiprasidoneCapsule20 mg/1OralREMEDYREPACK INC.2013-01-04Not applicableUs
ZiprasidoneCapsule80 mg/1OralREMEDYREPACK INC.2013-01-08Not applicableUs
ZiprasidoneCapsule60 mg/1OralREMEDYREPACK INC.2013-03-27Not applicableUs
ZiprasidoneCapsule20 mg/1OralGreenstone LLC2001-02-05Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ziprasidone HydrochlorideCapsule60 mg/1OralSandoz Inc2013-02-13Not applicableUs
Ziprasidone HydrochlorideCapsule20 mg/1OralClinical Solutions Wholesale2012-05-14Not applicableUs
Ziprasidone HydrochlorideCapsule40 mg/1OralWockhardt USA LLC.2012-09-01Not applicableUs
Ziprasidone HydrochlorideCapsule80 mg/1OralAmerican Health Packaging2014-12-04Not applicableUs
Ziprasidone HydrochlorideCapsule60 mg/1OralMylan Institutional Inc.2014-09-30Not applicableUs
Ziprasidone HydrochlorideCapsule60 mg/1OralWockhardt Limited2012-09-01Not applicableUs
Ziprasidone HydrochlorideCapsule20 mg/1OralMylan Pharmaceuticals Inc.2014-06-24Not applicableUs
Ziprasidone HydrochlorideCapsule20 mg/1OralLUPIN LIMITED2012-03-02Not applicableUs
Ziprasidone HydrochlorideCapsule80 mg/1OralREMEDYREPACK INC.2016-02-10Not applicableUs
Ziprasidone HydrochlorideCapsule60 mg/1OralApotex Corp.2012-05-14Not applicableUs
Ziprasidone HydrochlorideCapsule20 mg/1OralBlue Point Laboratories2014-02-26Not applicableUs
Ziprasidone HydrochlorideCapsule60 mg/1OralRebel Distributors Corp2012-03-02Not applicableUs
Ziprasidone HydrochlorideCapsule20 mg/1OralCardinal Health2012-03-15Not applicableUs
Ziprasidone HydrochlorideCapsule60 mg/1OralTYA Pharmaceuticals2012-09-01Not applicableUs
Ziprasidone HydrochlorideCapsule80 mg/1OralLupin Pharmaceuticals, Inc.2012-03-02Not applicableUs
Ziprasidone HydrochlorideCapsule20 mg/1OralDr. Reddy's Laboratories Limited2012-03-02Not applicableUs
Ziprasidone HydrochlorideCapsule60 mg/1OralGolden State Medical Supply, Inc.2012-05-14Not applicableUs
Ziprasidone HydrochlorideCapsule60 mg/1OralMajor Pharmaceuticals2012-03-15Not applicableUs
Ziprasidone HydrochlorideCapsule40 mg/1OralREMEDYREPACK INC.2014-10-21Not applicableUs
Ziprasidone HydrochlorideCapsule20 mg/1OralProficient Rx LP2012-05-14Not applicableUs
Ziprasidone HydrochlorideCapsule20 mg/1OralAmerican Health Packaging2014-12-04Not applicableUs
Ziprasidone HydrochlorideCapsule20 mg/1OralUnit Dose Services2012-03-02Not applicableUs
Ziprasidone HydrochlorideCapsule60 mg/1OralCardinal Health2013-07-02Not applicableUs
Ziprasidone HydrochlorideCapsule80 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-03-02Not applicableUs
Ziprasidone HydrochlorideCapsule60 mg/1OralREMEDYREPACK INC.2013-02-082016-10-13Us
Ziprasidone HydrochlorideCapsule40 mg/1OralREMEDYREPACK INC.2016-07-25Not applicableUs
Ziprasidone HydrochlorideCapsule80 mg/1OralWockhardt Limited2012-09-01Not applicableUs
Ziprasidone HydrochlorideCapsule80 mg/1OralSandoz Inc2013-02-13Not applicableUs
Ziprasidone HydrochlorideCapsule40 mg/1OralClinical Solutions Wholesale2012-05-14Not applicableUs
Ziprasidone HydrochlorideCapsule60 mg/1OralWockhardt USA LLC.2012-09-01Not applicableUs
Ziprasidone HydrochlorideCapsule20 mg/1OralLupin Pharmaceuticals, Inc.2012-03-02Not applicableUs
Ziprasidone HydrochlorideCapsule80 mg/1OralMylan Institutional Inc.2014-09-30Not applicableUs
Ziprasidone HydrochlorideCapsule80 mg/1OralRebel Distributors Corp2012-03-02Not applicableUs
Ziprasidone HydrochlorideCapsule40 mg/1OralCardinal Health2012-03-15Not applicableUs
Ziprasidone HydrochlorideCapsule40 mg/1OralMylan Pharmaceuticals Inc.2014-06-24Not applicableUs
Ziprasidone HydrochlorideCapsule40 mg/1OralLUPIN LIMITED2012-03-02Not applicableUs
Ziprasidone HydrochlorideCapsule60 mg/1OralREMEDYREPACK INC.2016-02-25Not applicableUs
Ziprasidone HydrochlorideCapsule80 mg/1OralApotex Corp.2012-05-14Not applicableUs
Ziprasidone HydrochlorideCapsule40 mg/1OralBlue Point Laboratories2014-02-26Not applicableUs
Ziprasidone HydrochlorideCapsule80 mg/1OralTYA Pharmaceuticals2012-09-01Not applicableUs
Ziprasidone HydrochlorideCapsule40 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2012-03-02Not applicableUs
Ziprasidone HydrochlorideCapsule40 mg/1OralDr. Reddy's Laboratories Limited2012-03-02Not applicableUs
Ziprasidone HydrochlorideCapsule80 mg/1OralGolden State Medical Supply, Inc.2012-05-14Not applicableUs
Ziprasidone HydrochlorideCapsule80 mg/1OralMajor Pharmaceuticals2012-03-15Not applicableUs
Ziprasidone HydrochlorideCapsule20 mg/1OralREMEDYREPACK INC.2014-10-30Not applicableUs
Ziprasidone HydrochlorideCapsule60 mg/1OralProficient Rx LP2012-05-14Not applicableUs
Ziprasidone HydrochlorideCapsule40 mg/1OralAmerican Health Packaging2014-12-04Not applicableUs
Ziprasidone HydrochlorideCapsule20 mg/1OralMylan Institutional Inc.2014-09-30Not applicableUs
Ziprasidone HydrochlorideCapsule20 mg/1OralWockhardt Limited2012-09-01Not applicableUs
Ziprasidone HydrochlorideCapsule20 mg/1OralSandoz Inc2013-02-13Not applicableUs
Ziprasidone HydrochlorideCapsule20 mg/1OralREMEDYREPACK INC.2012-03-29Not applicableUs
Ziprasidone HydrochlorideCapsule80 mg/1OralREMEDYREPACK INC.2016-08-19Not applicableUs
Ziprasidone HydrochlorideCapsule40 mg/1OralREMEDYREPACK INC.2014-04-25Not applicableUs
Ziprasidone HydrochlorideCapsule20 mg/1OralGolden State Medical Supply, Inc.2012-05-14Not applicableUs
Ziprasidone HydrochlorideCapsule20 mg/1OralMajor Pharmaceuticals2012-03-15Not applicableUs
Ziprasidone HydrochlorideCapsule60 mg/1OralClinical Solutions Wholesale2012-05-14Not applicableUs
Ziprasidone HydrochlorideCapsule80 mg/1OralWockhardt USA LLC.2012-09-01Not applicableUs
Ziprasidone HydrochlorideCapsule40 mg/1OralLupin Pharmaceuticals, Inc.2012-03-02Not applicableUs
Ziprasidone HydrochlorideCapsule40 mg/1OralREMEDYREPACK INC.2013-02-082016-10-13Us
Ziprasidone HydrochlorideCapsule80 mg/1OralCardinal Health2012-03-15Not applicableUs
Ziprasidone HydrochlorideCapsule60 mg/1OralMylan Pharmaceuticals Inc.2014-06-24Not applicableUs
Ziprasidone HydrochlorideCapsule60 mg/1OralLUPIN LIMITED2012-03-02Not applicableUs
Ziprasidone HydrochlorideCapsule20 mg/1OralREMEDYREPACK INC.2016-03-01Not applicableUs
Ziprasidone HydrochlorideCapsule20 mg/1OralProficient Rx LP2013-02-13Not applicableUs
Ziprasidone HydrochlorideCapsule60 mg/1OralBlue Point Laboratories2014-02-26Not applicableUs
Ziprasidone HydrochlorideCapsule20 mg/1OralTYA Pharmaceuticals2013-02-13Not applicableUs
Ziprasidone HydrochlorideCapsule80 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2012-03-02Not applicableUs
Ziprasidone HydrochlorideCapsule60 mg/1OralDr. Reddy's Laboratories Limited2012-03-02Not applicableUs
Ziprasidone HydrochlorideCapsule20 mg/1OralApotex Corp.2012-05-14Not applicableUs
Ziprasidone HydrochlorideCapsule20 mg/1OralRebel Distributors Corp2012-03-02Not applicableUs
Ziprasidone HydrochlorideCapsule80 mg/1OralREMEDYREPACK INC.2014-11-11Not applicableUs
Ziprasidone HydrochlorideCapsule20 mg/1OralREMEDYREPACK INC.2014-03-03Not applicableUs
Ziprasidone HydrochlorideCapsule20 mg/1OralWockhardt USA LLC.2012-09-01Not applicableUs
Ziprasidone HydrochlorideCapsule60 mg/1OralAmerican Health Packaging2014-12-04Not applicableUs
Ziprasidone HydrochlorideCapsule40 mg/1OralMylan Institutional Inc.2014-09-30Not applicableUs
Ziprasidone HydrochlorideCapsule40 mg/1OralWockhardt Limited2012-09-01Not applicableUs
Ziprasidone HydrochlorideCapsule40 mg/1OralSandoz Inc2013-02-13Not applicableUs
Ziprasidone HydrochlorideCapsule60 mg/1OralLupin Pharmaceuticals, Inc.2012-03-02Not applicableUs
Ziprasidone HydrochlorideCapsule60 mg/1OralREMEDYREPACK INC.2014-06-24Not applicableUs
Ziprasidone HydrochlorideCapsule40 mg/1OralGolden State Medical Supply, Inc.2012-05-14Not applicableUs
Ziprasidone HydrochlorideCapsule40 mg/1OralMajor Pharmaceuticals2012-03-15Not applicableUs
Ziprasidone HydrochlorideCapsule80 mg/1OralClinical Solutions Wholesale2012-05-14Not applicableUs
Ziprasidone HydrochlorideCapsule80 mg/1OralTYA Pharmaceuticals2012-03-02Not applicableUs
Ziprasidone HydrochlorideCapsule40 mg/1OralProficient Rx LP2012-05-14Not applicableUs
Ziprasidone HydrochlorideCapsule80 mg/1OralBlue Point Laboratories2014-02-26Not applicableUs
Ziprasidone HydrochlorideCapsule80 mg/1OralREMEDYREPACK INC.2013-02-152016-10-13Us
Ziprasidone HydrochlorideCapsule60 mg/1OralCardinal Health2012-03-15Not applicableUs
Ziprasidone HydrochlorideCapsule80 mg/1OralMylan Pharmaceuticals Inc.2014-06-24Not applicableUs
Ziprasidone HydrochlorideCapsule80 mg/1OralLUPIN LIMITED2012-03-02Not applicableUs
Ziprasidone HydrochlorideCapsule20 mg/1OralREMEDYREPACK INC.2016-07-25Not applicableUs
Ziprasidone HydrochlorideCapsule40 mg/1OralRebel Distributors Corp2012-03-02Not applicableUs
Ziprasidone HydrochlorideCapsule40 mg/1OralREMEDYREPACK INC.2016-02-10Not applicableUs
Ziprasidone HydrochlorideCapsule80 mg/1OralTYA Pharmaceuticals2013-02-13Not applicableUs
Ziprasidone HydrochlorideCapsule60 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2012-03-02Not applicableUs
Ziprasidone HydrochlorideCapsule80 mg/1OralDr. Reddy's Laboratories Limited2012-03-02Not applicableUs
Ziprasidone HydrochlorideCapsule40 mg/1OralApotex Corp.2012-05-14Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Ziprasidone hydrochloride
122883-93-6
Thumb
  • InChI Key: NZDBKBRIBJLNNT-UHFFFAOYSA-N
  • Monoisotopic Mass: 448.0891379
  • Average Mass: 449.39
DBSALT000810
Ziprasidone mesylate trihydrate
Thumb
  • InChI Key: WLQZEFFFIUHSJB-UHFFFAOYSA-N
  • Monoisotopic Mass: 562.132268453
  • Average Mass: 563.087
DBSALT000811
Categories
UNII6UKA5VEJ6X
CAS number146939-27-7
WeightAverage: 412.936
Monoisotopic: 412.112459711
Chemical FormulaC21H21ClN4OS
InChI KeyMVWVFYHBGMAFLY-UHFFFAOYSA-N
InChI
InChI=1S/C21H21ClN4OS/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11,13H,5-10,12H2,(H,23,27)
IUPAC Name
5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-2,3-dihydro-1H-indol-2-one
SMILES
ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1
Pharmacology
IndicationFor the treatment of schizophrenia and related psychotic disorders.
Structured Indications
PharmacodynamicsZiprasidone is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives and is indicated for the treatment of schizophrenia. Ziprasidone is a selective monoaminergic antagonist with high affinity for the serotonin Type 2 (5HT2), dopamine Type 2 (D2), 1 and 2 adrenergic, and H1 histaminergic receptors. Ziprasidone acts as an antagonist at other receptors, but with lower potency. Antagonism at receptors other than dopamine and 5HT2 with similar receptor affinities may explain some of the other therapeutic and side effects of Ziprasidone. Ziprasidone's antagonism of muscarinic M1-5 receptors may explain its anticholinergic effects. Ziprasidone's antagonism of histamine H1 receptors may explain the somnolence observed with this drug. Ziprasidone's antagonism of adrenergic a1 receptors may explain the orthostatic hypotension observed with this drug. Ziprasidone functions as an antagonist at the Dopamine D2 , 5HT-2A , and 5HT-1D receptors, and as an agonist at the 5HT-1A receptor. Ziprasidone also inhibits synaptic reuptake of serotonin and norepinephrine.
Mechanism of actionZiprasidone's antipsychotic activity is likely due to a combination of its antagonistic function at D2 receptors in the mesolimbic pathways and at 5HT2A receptors in the frontal cortex. Alleviation of positive symptoms is due to antagonism at D2 receptors while relief of negative symptoms are due to 5HT2A antagonism.
TargetKindPharmacological actionActionsOrganismUniProt ID
D(2) dopamine receptorProteinyes
antagonist
HumanP14416 details
5-hydroxytryptamine receptor 2AProteinyes
antagonist
HumanP28223 details
D(1A) dopamine receptorProteinunknown
antagonist
HumanP21728 details
D(1B) dopamine receptorProteinunknown
antagonist
HumanP21918 details
D(3) dopamine receptorProteinunknown
antagonist
HumanP35462 details
D(4) dopamine receptorProteinunknown
antagonist
HumanP21917 details
5-hydroxytryptamine receptor 1AProteinunknown
agonist
HumanP08908 details
5-hydroxytryptamine receptor 1BProteinunknown
antagonist
HumanP28222 details
5-hydroxytryptamine receptor 1DProteinunknown
antagonist
HumanP28221 details
5-hydroxytryptamine receptor 1EProteinunknown
antagonist
HumanP28566 details
5-hydroxytryptamine receptor 2CProteinunknown
antagonist
HumanP28335 details
5-hydroxytryptamine receptor 3AProteinunknown
antagonist
HumanP46098 details
5-hydroxytryptamine receptor 6Proteinunknown
antagonist
HumanP50406 details
5-hydroxytryptamine receptor 7Proteinunknown
antagonist
HumanP34969 details
Histamine H1 receptorProteinno
antagonist
HumanP35367 details
Alpha-1A adrenergic receptorProteinno
antagonist
HumanP35348 details
Alpha-1B adrenergic receptorProteinno
antagonist
HumanP35368 details
Alpha-2A adrenergic receptorProteinno
antagonist
HumanP08913 details
Alpha-2B adrenergic receptorProteinno
antagonist
HumanP18089 details
Alpha-2C adrenergic receptorProteinno
antagonist
HumanP18825 details
Muscarinic acetylcholine receptor M1Proteinno
antagonist
HumanP11229 details
Muscarinic acetylcholine receptor M2Proteinno
antagonist
HumanP08172 details
Muscarinic acetylcholine receptor M3Proteinno
antagonist
HumanP20309 details
Muscarinic acetylcholine receptor M4Proteinno
antagonist
HumanP08173 details
Muscarinic acetylcholine receptor M5Proteinno
antagonist
HumanP08912 details
Related Articles
Absorption~60%
Volume of distribution
  • 1.5 L/kg
Protein binding99%
Metabolism

Hepatic

SubstrateEnzymesProduct
Ziprasidone
benzisothiazole piperazineDetails
Route of eliminationZiprasidone is extensively metabolized after oral administration with only a small amount excreted in the urine (<1%) or feces (<4%) as unchanged drug. Approximately 20% of the dose is excreted in the urine, with approximately 66% being eliminated in the feces.
Half life7 hours
Clearance
  • 7.5 mL/min/kg
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamineZiprasidone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineZiprasidone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineZiprasidone may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineZiprasidone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Ziprasidone.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Ziprasidone is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Ziprasidone can be increased when it is combined with Abiraterone.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Ziprasidone.Approved, Investigational
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Ziprasidone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Aceprometazine.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Ziprasidone.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Ziprasidone.Withdrawn
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Ziprasidone.Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Ziprasidone.Approved
adipiplonThe risk or severity of adverse effects can be increased when Ziprasidone is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Agomelatine.Approved, Investigational
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Ziprasidone.Experimental
AjmalineThe metabolism of Ajmaline can be decreased when combined with Ziprasidone.Approved
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Ziprasidone.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Ziprasidone.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Alfaxalone.Vet Approved
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Ziprasidone.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Ziprasidone.Approved, Investigational
AliskirenThe metabolism of Aliskiren can be decreased when combined with Ziprasidone.Approved, Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Ziprasidone.Approved
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Ziprasidone.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Ziprasidone.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Ziprasidone.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Ziprasidone.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Ziprasidone.Approved, Withdrawn
AmantadineAmantadine may increase the QTc-prolonging activities of Ziprasidone.Approved
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Ziprasidone.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Ziprasidone.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Ziprasidone.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Ziprasidone.Approved
AmiodaroneZiprasidone may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Amisulpride.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Ziprasidone.Approved
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Ziprasidone.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Amobarbital.Approved, Illicit
AmoxapineAmoxapine may increase the QTc-prolonging activities of Ziprasidone.Approved
AmperozideThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Amperozide.Experimental
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Ziprasidone.Approved, Illicit
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Ziprasidone.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Ziprasidone.Approved
AnagrelideZiprasidone may increase the QTc-prolonging activities of Anagrelide.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Ziprasidone.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Ziprasidone.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Ziprasidone.Approved, Investigational
ApremilastThe metabolism of Apremilast can be decreased when combined with Ziprasidone.Approved, Investigational
AprepitantThe serum concentration of Ziprasidone can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Ziprasidone.Approved
ArformoterolArformoterol may increase the QTc-prolonging activities of Ziprasidone.Approved, Investigational
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Ziprasidone.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Ziprasidone.Approved, Investigational
Arsenic trioxideZiprasidone may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherZiprasidone may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Articaine.Approved
AsenapineZiprasidone may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Ziprasidone.Approved, Withdrawn
AtazanavirThe metabolism of Ziprasidone can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Ziprasidone.Approved
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Ziprasidone.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Ziprasidone.Approved
AxitinibThe metabolism of Axitinib can be decreased when combined with Ziprasidone.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Azaperone.Vet Approved
AzelastineZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe metabolism of Azelastine can be decreased when combined with Ziprasidone.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Ziprasidone.Approved
BaclofenThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Baclofen.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Ziprasidone.Investigational
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Ziprasidone.Investigational
BarbitalThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Barbital.Illicit
BedaquilineBedaquiline may increase the QTc-prolonging activities of Ziprasidone.Approved
BenperidolThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Benperidol.Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Ziprasidone.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Benzocaine.Approved
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Ziprasidone.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Ziprasidone.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Ziprasidone.Approved, Withdrawn
BetaxololThe metabolism of Betaxolol can be decreased when combined with Ziprasidone.Approved
BexaroteneThe serum concentration of Ziprasidone can be decreased when it is combined with Bexarotene.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Ziprasidone.Approved
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Ziprasidone.Approved
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Ziprasidone.Approved
BoceprevirThe metabolism of Ziprasidone can be decreased when combined with Boceprevir.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Ziprasidone.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Ziprasidone.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Ziprasidone.Approved
Brentuximab vedotinThe metabolism of Brentuximab vedotin can be decreased when combined with Ziprasidone.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Ziprasidone.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.Approved
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Ziprasidone.Approved
BromazepamThe metabolism of Bromazepam can be decreased when combined with Ziprasidone.Approved, Illicit
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Ziprasidone.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Ziprasidone.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Brotizolam.Approved, Withdrawn
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Ziprasidone.Approved
BudesonideThe metabolism of Budesonide can be decreased when combined with Ziprasidone.Approved
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Ziprasidone.Withdrawn
BufuralolThe metabolism of Bufuralol can be decreased when combined with Ziprasidone.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Ziprasidone.Approved, Investigational
BuprenorphineZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Ziprasidone.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Ziprasidone.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Ziprasidone.Approved, Investigational
BusulfanThe metabolism of Busulfan can be decreased when combined with Ziprasidone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ziprasidone.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Butorphanol.Approved, Illicit, Vet Approved
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Ziprasidone.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Ziprasidone.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Ziprasidone.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Ziprasidone.Approved
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Ziprasidone.Approved, Nutraceutical
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Ziprasidone.Approved
CaptoprilThe metabolism of Captopril can be decreased when combined with Ziprasidone.Approved
CarbamazepineThe serum concentration of Ziprasidone can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Ziprasidone.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Carfentanil.Illicit, Vet Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Ziprasidone.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Carisoprodol.Approved
CarteololThe metabolism of Carteolol can be decreased when combined with Ziprasidone.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Ziprasidone.Approved, Investigational
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Ziprasidone.Experimental
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Ziprasidone.Approved, Investigational
CeliprololThe metabolism of Celiprolol can be decreased when combined with Ziprasidone.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Ziprasidone.Approved, Vet Approved
CeritinibThe serum concentration of Ziprasidone can be increased when it is combined with Ceritinib.Approved
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Ziprasidone.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Cetirizine.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Ziprasidone.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Ziprasidone.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Ziprasidone.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Chloroprocaine.Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Ziprasidone.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Ziprasidone.Approved
ChlorphentermineZiprasidone may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Ziprasidone.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Ziprasidone.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Ziprasidone.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Ziprasidone.Approved, Nutraceutical
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Ziprasidone.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Ziprasidone.Experimental
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Ziprasidone.Approved
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Ziprasidone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Cinchocaine.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Ziprasidone.Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Ziprasidone.Approved, Investigational
CisaprideZiprasidone may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramCitalopram may increase the QTc-prolonging activities of Ziprasidone.Approved
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Ziprasidone.Approved
ClemastineThe metabolism of Ziprasidone can be decreased when combined with Clemastine.Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Ziprasidone.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Clidinium.Approved
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Ziprasidone.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Ziprasidone.Approved, Illicit
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Ziprasidone.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Ziprasidone.Approved
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Ziprasidone.Investigational
ClomipramineClomipramine may increase the QTc-prolonging activities of Ziprasidone.Approved, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Ziprasidone.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Ziprasidone.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Ziprasidone.Approved, Nutraceutical
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Ziprasidone.Approved, Illicit
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Ziprasidone.Approved, Illicit
ClotrimazoleThe metabolism of Ziprasidone can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Ziprasidone.Approved
CobicistatThe metabolism of Ziprasidone can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Ziprasidone.Approved
CocaineThe metabolism of Cocaine can be decreased when combined with Ziprasidone.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Ziprasidone.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Ziprasidone.Approved
ConivaptanThe serum concentration of Ziprasidone can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Ziprasidone.Approved
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Ziprasidone.Approved
CrizotinibCrizotinib may increase the QTc-prolonging activities of Ziprasidone.Approved
CyclizineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Cyclizine.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Ziprasidone.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Ziprasidone.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Ziprasidone.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Ziprasidone can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
CytarabineThe metabolism of Cytarabine can be decreased when combined with Ziprasidone.Approved, Investigational
DabrafenibThe serum concentration of Ziprasidone can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Ziprasidone.Approved
DantroleneThe metabolism of Dantrolene can be decreased when combined with Ziprasidone.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Ziprasidone.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dapiprazole.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Ziprasidone.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Ziprasidone.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Ziprasidone.Approved, Investigational
DarunavirThe metabolism of Ziprasidone can be decreased when combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Ziprasidone.Approved
DasatinibThe serum concentration of Ziprasidone can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Ziprasidone.Approved
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Ziprasidone.Approved
DeferasiroxThe serum concentration of Ziprasidone can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Ziprasidone.Approved
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Ziprasidone.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Ziprasidone.Investigational
deramciclaneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with deramciclane.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Ziprasidone.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Ziprasidone.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Ziprasidone.Approved
DetomidineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Ziprasidone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dexbrompheniramine.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Ziprasidone.Approved, Illicit, Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Ziprasidone.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Ziprasidone.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Ziprasidone.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Ziprasidone.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dezocine.Approved
DiazepamThe metabolism of Diazepam can be decreased when combined with Ziprasidone.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Ziprasidone.Approved, Vet Approved
DiethylpropionZiprasidone may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Difenoxin.Approved, Illicit
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Ziprasidone.Approved
DigoxinThe metabolism of Digoxin can be decreased when combined with Ziprasidone.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Ziprasidone.Approved, Illicit
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Ziprasidone.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Ziprasidone.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dimenhydrinate.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Ziprasidone.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Diphenoxylate.Approved, Illicit
DisopyramideZiprasidone may increase the QTc-prolonging activities of Disopyramide.Approved
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Ziprasidone.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Ziprasidone.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Ziprasidone.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Ziprasidone.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Ziprasidone.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Ziprasidone.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Ziprasidone.Approved
DoramectinThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Doramectin.Vet Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Ziprasidone.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Ziprasidone.Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Ziprasidone.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Ziprasidone.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Ziprasidone.Approved, Investigational
DoxycyclineThe metabolism of Ziprasidone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Ziprasidone is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.Approved, Illicit
DronedaroneZiprasidone may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Drotebanol.Experimental, Illicit
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Ziprasidone.Approved
DuloxetineThe metabolism of Duloxetine can be decreased when combined with Ziprasidone.Approved
DutasterideThe metabolism of Dutasteride can be decreased when combined with Ziprasidone.Approved, Investigational
DyclonineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Ziprasidone is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Ziprasidone can be decreased when it is combined with Efavirenz.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Ziprasidone.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Ziprasidone.Approved
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Ziprasidone.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ziprasidone.Approved
EnalaprilThe metabolism of Enalapril can be decreased when combined with Ziprasidone.Approved, Vet Approved
EncainideThe metabolism of Encainide can be decreased when combined with Ziprasidone.Approved, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Ziprasidone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Ziprasidone.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Ziprasidone can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Ziprasidone.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Ziprasidone.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Ziprasidone.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Ziprasidone.Approved
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Ziprasidone.Approved
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Ziprasidone.Approved
EribulinEribulin may increase the QTc-prolonging activities of Ziprasidone.Approved, Investigational
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Ziprasidone.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Ziprasidone.Approved, Vet Approved
EscitalopramZiprasidone may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Ziprasidone can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Ziprasidone.Investigational
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Ziprasidone.Approved, Investigational
EstazolamThe metabolism of Estazolam can be decreased when combined with Ziprasidone.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Ziprasidone.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Ziprasidone.Approved
EstramustineThe metabolism of Estramustine can be decreased when combined with Ziprasidone.Approved
EstroneThe metabolism of Estrone can be decreased when combined with Ziprasidone.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Ziprasidone.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Ziprasidone.Approved
EthanolZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ziprasidone.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Ziprasidone.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Ziprasidone.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Ziprasidone.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Etomidate.Approved
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Ziprasidone.Approved, Investigational
EtoperidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Etoperidone.Approved
EtoposideThe metabolism of Etoposide can be decreased when combined with Ziprasidone.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Ziprasidone.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Ziprasidone can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Ziprasidone.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Ziprasidone.Approved, Investigational
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Ziprasidone.Approved, Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Ziprasidone.Approved
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Ziprasidone.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Ziprasidone.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Ziprasidone.Approved
FelodipineThe metabolism of Felodipine can be decreased when combined with Ziprasidone.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Ziprasidone.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Ziprasidone.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ziprasidone.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Fexofenadine.Approved
FinasterideThe metabolism of Finasteride can be decreased when combined with Ziprasidone.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Ziprasidone.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Ziprasidone.Approved, Withdrawn
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Ziprasidone.Approved
FluconazoleFluconazole may increase the QTc-prolonging activities of Ziprasidone.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Fludiazepam.Approved, Illicit
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Ziprasidone.Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Ziprasidone.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Ziprasidone.Approved, Illicit
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Ziprasidone.Approved
FluoxetineFluoxetine may increase the QTc-prolonging activities of Ziprasidone.Approved, Vet Approved
FlupentixolZiprasidone may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Ziprasidone.Approved
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Ziprasidone.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Fluspirilene.Approved
FlutamideThe metabolism of Flutamide can be decreased when combined with Ziprasidone.Approved
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Ziprasidone.Approved
Fluticasone PropionateThe metabolism of Fluticasone Propionate can be decreased when combined with Ziprasidone.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Ziprasidone.Approved
FluvoxamineThe metabolism of Ziprasidone can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Ziprasidone.Approved, Investigational
FosamprenavirThe metabolism of Fosamprenavir can be decreased when combined with Ziprasidone.Approved
FosaprepitantThe serum concentration of Ziprasidone can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Ziprasidone.Approved
FosphenytoinThe metabolism of Ziprasidone can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Ziprasidone.Approved, Investigational
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Ziprasidone.Approved, Investigational
Fusidic AcidThe serum concentration of Ziprasidone can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Ziprasidone is combined with gabapentin enacarbil.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Ziprasidone.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Ziprasidone.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GefitinibThe metabolism of Gefitinib can be decreased when combined with Ziprasidone.Approved, Investigational
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Ziprasidone.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Ziprasidone.Approved, Investigational
GepironeThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Gepirone.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Ziprasidone.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Ziprasidone.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Ziprasidone.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Ziprasidone.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Ziprasidone.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Glutethimide.Approved, Illicit
GlyburideThe metabolism of Glyburide can be decreased when combined with Ziprasidone.Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Ziprasidone.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Ziprasidone.Approved, Investigational
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Ziprasidone.Withdrawn
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Ziprasidone.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Ziprasidone.Investigational
HalazepamThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Halazepam.Approved, Illicit, Withdrawn
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Ziprasidone.Approved
HaloperidolHaloperidol may increase the QTc-prolonging activities of Ziprasidone.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Ziprasidone.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Heroin.Approved, Illicit
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Ziprasidone.Approved
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Ziprasidone.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Ziprasidone.Approved
HydrocodoneZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Ziprasidone.Approved, Vet Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Ziprasidone.Approved, Illicit
Hydroxyamphetamine hydrobromideZiprasidone may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Ziprasidone.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Ziprasidone.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Ziprasidone.Approved
IbutilideZiprasidone may increase the QTc-prolonging activities of Ibutilide.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Ziprasidone.Approved
IdelalisibThe serum concentration of Ziprasidone can be increased when it is combined with Idelalisib.Approved
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Ziprasidone resulting in a loss in efficacy.Approved
IloperidoneZiprasidone may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Ziprasidone.Approved
ImipramineImipramine may increase the QTc-prolonging activities of Ziprasidone.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Ziprasidone.Approved, Investigational
IndacaterolIndacaterol may increase the QTc-prolonging activities of Ziprasidone.Approved
IndalpineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Ziprasidone.Approved
IndinavirThe metabolism of Ziprasidone can be decreased when combined with Indinavir.Approved
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Ziprasidone.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Ziprasidone.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Ziprasidone.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Ziprasidone.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Ziprasidone.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Ziprasidone.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Ziprasidone.Approved
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Ziprasidone.Approved, Investigational
IsavuconazoniumThe metabolism of Isavuconazonium can be decreased when combined with Ziprasidone.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Ziprasidone.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Ziprasidone.Approved, Vet Approved
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Ziprasidone.Approved
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Ziprasidone.Approved
IsradipineIsradipine may increase the QTc-prolonging activities of Ziprasidone.Approved
ItraconazoleThe metabolism of Ziprasidone can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Ziprasidone.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Ziprasidone.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Ziprasidone.Approved, Vet Approved
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Ziprasidone.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Ziprasidone.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Ziprasidone.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be decreased when combined with Ziprasidone.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Ziprasidone.Approved
KetoconazoleThe metabolism of Ziprasidone can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe metabolism of Labetalol can be decreased when combined with Ziprasidone.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Lamotrigine.Approved, Investigational
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Ziprasidone.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Ziprasidone.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Ziprasidone.Investigational
LenvatinibLenvatinib may increase the QTc-prolonging activities of Ziprasidone.Approved
LercanidipineThe metabolism of Lercanidipine can be decreased when combined with Ziprasidone.Approved, Investigational
LetrozoleThe metabolism of Letrozole can be decreased when combined with Ziprasidone.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Ziprasidone.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Ziprasidone.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Levocabastine.Approved
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Ziprasidone.Approved
LevodopaThe therapeutic efficacy of Levodopa can be decreased when used in combination with Ziprasidone.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Ziprasidone.Approved, Investigational
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Ziprasidone.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Ziprasidone.Approved
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Ziprasidone.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Levorphanol.Approved
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Ziprasidone.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Ziprasidone.Approved, Vet Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Ziprasidone.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Ziprasidone.Approved, Investigational
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Ziprasidone.Approved
LisdexamfetamineZiprasidone may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Ziprasidone.Approved
LithiumLithium may increase the neurotoxic activities of Ziprasidone.Approved
LofentanilThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Lofentanil.Illicit
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Ziprasidone.Approved
LomustineThe metabolism of Lomustine can be decreased when combined with Ziprasidone.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Ziprasidone.Approved
LopinavirZiprasidone may increase the QTc-prolonging activities of Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Ziprasidone.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ziprasidone.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Ziprasidone.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Ziprasidone.Approved
LovastatinThe metabolism of Ziprasidone can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Loxapine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Ziprasidone is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Ziprasidone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Ziprasidone can be increased when combined with Lumacaftor.Approved
LumefantrineZiprasidone may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Ziprasidone.Approved
MacitentanThe metabolism of Macitentan can be decreased when combined with Ziprasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.Approved, Vet Approved
MaprotilineMaprotiline may increase the QTc-prolonging activities of Ziprasidone.Approved
MaravirocThe metabolism of Maraviroc can be decreased when combined with Ziprasidone.Approved, Investigational
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Ziprasidone.Approved, Vet Approved
MeclizineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Medetomidine.Vet Approved
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Ziprasidone.Approved, Investigational
MefloquineMefloquine may increase the QTc-prolonging activities of Ziprasidone.Approved
MelatoninThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Ziprasidone.Approved, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Melperone.Approved
MephedroneZiprasidone may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineZiprasidone may decrease the stimulatory activities of Mephentermine.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Ziprasidone.Investigational, Withdrawn
MepivacaineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Meprobamate.Approved, Illicit
MequitazineZiprasidone may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Ziprasidone.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Metaxalone.Approved
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Ziprasidone.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Ziprasidone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Ziprasidone.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Methapyrilene.Withdrawn
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Ziprasidone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Methohexital.Approved
MethotrimeprazineZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Ziprasidone.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Ziprasidone.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Methsuximide.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Methylphenobarbital.Approved
MethylprednisoloneThe metabolism of Methylprednisolone can be decreased when combined with Ziprasidone.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Ziprasidone.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Ziprasidone.Approved, Illicit, Withdrawn
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Ziprasidone.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Ziprasidone.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Ziprasidone.Approved
MetyrosineZiprasidone may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Ziprasidone can be decreased when combined with Mexiletine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Ziprasidone.Approved
MibefradilThe metabolism of Mibefradil can be decreased when combined with Ziprasidone.Withdrawn
MiconazoleThe metabolism of Miconazole can be decreased when combined with Ziprasidone.Approved, Investigational, Vet Approved
MidazolamThe metabolism of Midazolam can be decreased when combined with Ziprasidone.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Ziprasidone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Ziprasidone.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Ziprasidone.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Ziprasidone.Approved
MinaprineThe metabolism of Minaprine can be decreased when combined with Ziprasidone.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.Approved, Investigational
MirabegronMirabegron may increase the QTc-prolonging activities of Ziprasidone.Approved
MirtazapineZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Ziprasidone.Approved, Investigational
MitotaneThe serum concentration of Ziprasidone can be decreased when it is combined with Mitotane.Approved
MMDAZiprasidone may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Ziprasidone.Approved
ModafinilThe serum concentration of Ziprasidone can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Ziprasidone.Approved
MolindoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Molindone.Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Ziprasidone.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Ziprasidone.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Ziprasidone.Approved, Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Ziprasidone.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.Approved, Investigational
NafcillinThe serum concentration of Ziprasidone can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Nalbuphine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Ziprasidone.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Ziprasidone.Approved, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Ziprasidone.Approved, Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Ziprasidone.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Ziprasidone.Approved, Investigational
NefazodoneThe metabolism of Ziprasidone can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Ziprasidone can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Ziprasidone can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Ziprasidone can be increased when combined with Nevirapine.Approved
NicardipineNicardipine may increase the QTc-prolonging activities of Ziprasidone.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Ziprasidone.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Ziprasidone.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Ziprasidone.Approved
NilotinibZiprasidone may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Ziprasidone.Approved
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Ziprasidone.Approved
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Ziprasidone.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Ziprasidone.Approved
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Ziprasidone.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Ziprasidone.Approved, Vet Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Nitrous oxide.Approved, Vet Approved
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Ziprasidone.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Ziprasidone.Approved
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Ziprasidone.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the QTc-prolonging activities of Ziprasidone.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Ziprasidone.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Ziprasidone.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Ziprasidone.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Ziprasidone.Approved
OlodaterolOlodaterol may increase the QTc-prolonging activities of Ziprasidone.Approved
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Ziprasidone.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Ziprasidone.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Ziprasidone.Approved
OpiumThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Opium.Approved, Illicit
OrphenadrineZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Ziprasidone can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Ziprasidone.Approved
OxazepamThe metabolism of Oxazepam can be decreased when combined with Ziprasidone.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Oxybuprocaine.Approved
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Ziprasidone.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Ziprasidone.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Ziprasidone.Approved, Vet Approved
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Ziprasidone.Approved, Vet Approved
PalbociclibThe serum concentration of Ziprasidone can be increased when it is combined with Palbociclib.Approved
PaliperidoneZiprasidone may increase the QTc-prolonging activities of Paliperidone.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Ziprasidone.Approved, Investigational
PanobinostatPanobinostat may increase the QTc-prolonging activities of Ziprasidone.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Ziprasidone.Approved
ParaldehydeZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Ziprasidone.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Ziprasidone.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Ziprasidone.Approved
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Ziprasidone.Approved, Investigational
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Ziprasidone.Approved
ParoxetineParoxetine may increase the QTc-prolonging activities of Ziprasidone.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Ziprasidone.Approved
PazopanibPazopanib may increase the QTc-prolonging activities of Ziprasidone.Approved
Peginterferon alfa-2bThe serum concentration of Ziprasidone can be increased when it is combined with Peginterferon alfa-2b.Approved
PentamidinePentamidine may increase the QTc-prolonging activities of Ziprasidone.Approved
PentazocineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe metabolism of Ziprasidone can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.Approved
PerazineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Perazine.Investigational
PerflutrenPerflutren may increase the QTc-prolonging activities of Ziprasidone.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Ziprasidone.Approved, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Ziprasidone.Approved
PermethrinThe metabolism of Permethrin can be decreased when combined with Ziprasidone.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Perospirone.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Ziprasidone.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Ziprasidone.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Ziprasidone.Withdrawn
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Ziprasidone.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Ziprasidone.Approved, Withdrawn
PhenobarbitalThe metabolism of Ziprasidone can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Ziprasidone.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Phenoxyethanol.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Ziprasidone.Approved
PhentermineZiprasidone may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe metabolism of Ziprasidone can be increased when combined with Phenytoin.Approved, Vet Approved
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Ziprasidone.Approved
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Ziprasidone.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Ziprasidone.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Ziprasidone.Withdrawn
PindololThe metabolism of Pindolol can be decreased when combined with Ziprasidone.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Ziprasidone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Pipamperone.Approved
PiperazineThe metabolism of Piperazine can be decreased when combined with Ziprasidone.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Ziprasidone.Approved
PiribedilThe therapeutic efficacy of Piribedil can be decreased when used in combination with Ziprasidone.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Pizotifen.Approved
PodofiloxThe metabolism of Podofilox can be decreased when combined with Ziprasidone.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Ziprasidone.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Ziprasidone.Approved
PosaconazoleThe metabolism of Ziprasidone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleZiprasidone may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Ziprasidone.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Pramocaine.Approved
PrasteroneThe metabolism of Prasterone can be decreased when combined with Ziprasidone.Approved, Nutraceutical
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Ziprasidone.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Ziprasidone.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Ziprasidone.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Ziprasidone.Approved, Vet Approved
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Ziprasidone.Approved, Vet Approved
PrednisoneThe metabolism of Prednisone can be decreased when combined with Ziprasidone.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ziprasidone.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Prilocaine.Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Ziprasidone.Approved
PrimidoneThe metabolism of Ziprasidone can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideZiprasidone may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Ziprasidone.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Ziprasidone.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Ziprasidone.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Ziprasidone.Approved
PromazinePromazine may increase the QTc-prolonging activities of Ziprasidone.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Ziprasidone.Approved
PropafenoneThe serum concentration of Ziprasidone can be increased when it is combined with Propafenone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Proparacaine.Approved, Vet Approved
PropofolPropofol may increase the QTc-prolonging activities of Ziprasidone.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Propoxycaine.Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Ziprasidone.Approved, Investigational
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Ziprasidone.Approved
PSD502The risk or severity of adverse effects can be increased when Ziprasidone is combined with PSD502.Investigational
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Ziprasidone.Approved
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Ziprasidone.Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Ziprasidone.Approved, Illicit
QuetiapineZiprasidone may increase the QTc-prolonging activities of Quetiapine.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Ziprasidone.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Ziprasidone.Approved
QuinidineZiprasidone may increase the QTc-prolonging activities of Quinidine.Approved
QuinineZiprasidone may increase the QTc-prolonging activities of Quinine.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Ziprasidone.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Raclopride.Investigational
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Ziprasidone.Approved, Investigational
RamelteonThe metabolism of Ramelteon can be decreased when combined with Ziprasidone.Approved, Investigational
RanitidineThe metabolism of Ranitidine can be decreased when combined with Ziprasidone.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Ziprasidone.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Ziprasidone.Approved
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Ziprasidone.Approved, Investigational
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Ziprasidone.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Remifentanil.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Ziprasidone.Approved, Withdrawn
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Ziprasidone.Approved, Investigational
repinotanThe metabolism of repinotan can be decreased when combined with Ziprasidone.Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ziprasidone.Approved
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Ziprasidone.Approved
RifabutinThe metabolism of Ziprasidone can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Ziprasidone can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Ziprasidone can be increased when combined with Rifapentine.Approved
RilpivirineRilpivirine may increase the QTc-prolonging activities of Ziprasidone.Approved
RimonabantThe metabolism of Rimonabant can be decreased when combined with Ziprasidone.Approved, Investigational
RiociguatThe metabolism of Riociguat can be decreased when combined with Ziprasidone.Approved
RisperidoneRisperidone may increase the QTc-prolonging activities of Ziprasidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Ritanserin.Investigational
RitobegronZiprasidone may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe metabolism of Ziprasidone can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Ziprasidone.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Ziprasidone.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Ziprasidone.Investigational, Withdrawn
RolapitantThe metabolism of Rolapitant can be decreased when combined with Ziprasidone.Approved
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Ziprasidone.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Romifidine.Vet Approved
RopiniroleZiprasidone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Ziprasidone.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Ziprasidone.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Ziprasidone.Approved
RotigotineZiprasidone may increase the sedative activities of Rotigotine.Approved
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Ziprasidone.Approved, Withdrawn
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Ziprasidone.Approved
RuxolitinibThe metabolism of Ruxolitinib can be decreased when combined with Ziprasidone.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Ziprasidone is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Ziprasidone is combined with Sage 547.Investigational
SalbutamolSalbutamol may increase the QTc-prolonging activities of Ziprasidone.Approved, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Ziprasidone.Approved
SaquinavirSaquinavir may increase the QTc-prolonging activities of Ziprasidone.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Ziprasidone.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Ziprasidone.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Ziprasidone.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Ziprasidone.Approved, Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Ziprasidone.Approved, Withdrawn
SertralineSertraline may increase the QTc-prolonging activities of Ziprasidone.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Ziprasidone.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Ziprasidone.Approved, Illicit, Investigational, Withdrawn
SildenafilThe metabolism of Sildenafil can be decreased when combined with Ziprasidone.Approved, Investigational
SilodosinThe metabolism of Silodosin can be decreased when combined with Ziprasidone.Approved
SiltuximabThe serum concentration of Ziprasidone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Ziprasidone.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Ziprasidone.Approved
SirolimusThe metabolism of Sirolimus can be decreased when combined with Ziprasidone.Approved, Investigational
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Ziprasidone.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Ziprasidone.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Ziprasidone.Approved, Investigational
SorafenibSorafenib may increase the QTc-prolonging activities of Ziprasidone.Approved, Investigational
SotalolZiprasidone may increase the QTc-prolonging activities of Sotalol.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Ziprasidone.Experimental
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Ziprasidone.Approved
St. John's WortThe serum concentration of Ziprasidone can be decreased when it is combined with St. John&#39;s Wort.Nutraceutical
StiripentolThe serum concentration of Ziprasidone can be increased when it is combined with Stiripentol.Approved
SufentanilThe metabolism of Sufentanil can be decreased when combined with Ziprasidone.Approved, Investigational
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Ziprasidone.Approved, Vet Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Ziprasidone.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Ziprasidone.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Ziprasidone.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Ziprasidone.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Ziprasidone.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Ziprasidone.Approved, Investigational
SuvorexantZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Ziprasidone.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Ziprasidone.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Ziprasidone.Approved, Investigational
TadalafilThe metabolism of Tadalafil can be decreased when combined with Ziprasidone.Approved, Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Ziprasidone resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Ziprasidone.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Tasimelteon.Approved
TasosartanThe metabolism of Tasosartan can be decreased when combined with Ziprasidone.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Ziprasidone.Experimental
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Ziprasidone.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Ziprasidone.Investigational, Withdrawn
TelaprevirThe metabolism of Ziprasidone can be decreased when combined with Telaprevir.Approved
TelavancinTelavancin may increase the QTc-prolonging activities of Ziprasidone.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Ziprasidone.Approved
TemazepamThe metabolism of Temazepam can be decreased when combined with Ziprasidone.Approved
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Ziprasidone.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Ziprasidone.Approved
TenofovirThe metabolism of Ziprasidone can be decreased when combined with Tenofovir.Approved, Investigational
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Ziprasidone.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Ziprasidone.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Ziprasidone.Withdrawn
TeriflunomideThe serum concentration of Ziprasidone can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Ziprasidone.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Ziprasidone.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Ziprasidone.Approved
TetracaineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Tetracaine.Approved, Vet Approved
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Ziprasidone.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Tetrodotoxin.Investigational
ThalidomideZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Ziprasidone.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Thiamylal.Approved, Vet Approved
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Ziprasidone.Investigational
ThiopentalThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Thiopental.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Ziprasidone.Approved
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Ziprasidone.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Ziprasidone.Approved
TiagabineThe metabolism of Tiagabine can be decreased when combined with Ziprasidone.Approved
TiaprideThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Tiapride.Investigational
TicagrelorThe metabolism of Ticagrelor can be decreased when combined with Ziprasidone.Approved
TiclopidineThe metabolism of Ziprasidone can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Tiletamine.Vet Approved
TimololThe metabolism of Timolol can be decreased when combined with Ziprasidone.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Ziprasidone.Approved, Investigational
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Ziprasidone.Approved
TipranavirThe metabolism of Tipranavir can be decreased when combined with Ziprasidone.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Ziprasidone.Approved
TocilizumabThe serum concentration of Ziprasidone can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Ziprasidone.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Ziprasidone.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Ziprasidone.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Tolcapone.Approved, Withdrawn
TolterodineTolterodine may increase the QTc-prolonging activities of Ziprasidone.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Ziprasidone.Approved
TopiramateThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Topiramate.Approved
ToremifeneZiprasidone may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Ziprasidone.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Ziprasidone.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Tranylcypromine.Approved
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Ziprasidone.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Ziprasidone.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Ziprasidone.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Ziprasidone.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Ziprasidone.Approved, Vet Approved
TriazolamThe metabolism of Triazolam can be decreased when combined with Ziprasidone.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Triflupromazine.Approved, Vet Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Ziprasidone.Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Ziprasidone.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Ziprasidone.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Triprolidine.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Ziprasidone.Approved, Vet Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Ziprasidone.Withdrawn
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Ziprasidone.Approved
Uc1010The risk or severity of adverse effects can be increased when Ziprasidone is combined with Uc1010.Investigational
UdenafilThe metabolism of Udenafil can be decreased when combined with Ziprasidone.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Ziprasidone.Approved
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Ziprasidone.Approved
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Ziprasidone.Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Valproic Acid.Approved, Investigational
VandetanibZiprasidone may increase the QTc-prolonging activities of Vandetanib.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Ziprasidone.Investigational
VardenafilVardenafil may increase the QTc-prolonging activities of Ziprasidone.Approved
VemurafenibThe serum concentration of Ziprasidone can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Ziprasidone.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Ziprasidone.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Ziprasidone.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Ziprasidone.Investigational
VigabatrinThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Vigabatrin.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Ziprasidone.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Ziprasidone.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Ziprasidone.Approved, Investigational
VinblastineThe metabolism of Vinblastine can be decreased when combined with Ziprasidone.Approved
VincristineThe metabolism of Vincristine can be decreased when combined with Ziprasidone.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Ziprasidone.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Ziprasidone.Approved, Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Ziprasidone.Approved
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Ziprasidone.Approved, Investigational
VoriconazoleThe metabolism of Ziprasidone can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Ziprasidone.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Ziprasidone.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Ziprasidone.Approved
XylazineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Xylazine.Vet Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Ziprasidone.Approved, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Ziprasidone.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Ziprasidone.Approved
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Ziprasidone.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Ziconotide.Approved
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Ziprasidone.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Ziprasidone.Approved, Investigational, Withdrawn
ZimelidineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Zimelidine.Withdrawn
ZolazepamThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Ziprasidone.Approved, Investigational
ZolpidemZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Ziprasidone.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Ziprasidone.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Ziprasidone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Zotepine.Approved
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Ziprasidone.Approved, Investigational
Food Interactions
  • Avoid alcohol.
References
Synthesis Reference

Frank R. Busch, Carol A. Rose, “Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihy dro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist.” U.S. Patent US6110918, issued January, 1995.

US6110918
General References
  1. Stahl SM, Shayegan DK: The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64 Suppl 19:6-12. [PubMed:14728084 ]
  2. Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH: Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001 Aug 17;425(3):197-201. [PubMed:11513838 ]
External Links
ATC CodesN05AE04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (75 KB)
MSDSDownload (57.8 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9759
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.7167
P-glycoprotein inhibitor IInhibitor0.8052
P-glycoprotein inhibitor IIInhibitor0.6419
Renal organic cation transporterInhibitor0.5325
CYP450 2C9 substrateNon-substrate0.7972
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateSubstrate0.7408
CYP450 1A2 substrateInhibitor0.6576
CYP450 2C9 inhibitorInhibitor0.6329
CYP450 2D6 inhibitorNon-inhibitor0.7151
CYP450 2C19 inhibitorInhibitor0.8086
CYP450 3A4 inhibitorNon-inhibitor0.7723
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9567
Ames testNon AMES toxic0.6273
CarcinogenicityNon-carcinogens0.8672
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5877 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6826
hERG inhibition (predictor II)Inhibitor0.7753
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
Packagers
Dosage forms
FormRouteStrength
CapsuleOral20 mg
Injection, powder, lyophilized, for solutionIntramuscular20 mg/mL
CapsuleOral20.0 mg
CapsuleOral40 mg
CapsuleOral60 mg
CapsuleOral80 mg
CapsuleOral20 mg/1
CapsuleOral40 mg/1
CapsuleOral60 mg/1
CapsuleOral80 mg/1
Prices
Unit descriptionCostUnit
Zoladex 10.8 mg Implant Syringe1407.72USD syringe
Geodon 20 mg vial16.22USD vial
Geodon 60 mg capsule9.88USD capsule
Geodon 80 mg capsule9.88USD capsule
Geodon 20 mg capsule8.14USD capsule
Geodon 40 mg capsule8.14USD capsule
Zeldox 40 mg Capsule2.13USD capsule
Zeldox 60 mg Capsule2.13USD capsule
Zeldox 80 mg Capsule2.13USD capsule
Zeldox 20 mg Capsule1.86USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2105114 No2000-02-152013-08-30Canada
CA2256227 No2003-07-012018-12-16Canada
US5134127 No1993-01-232010-01-23Us
US6110918 No1997-03-262017-03-26Us
US6150366 No1999-05-272019-05-27Us
US6232304 No1997-04-012017-04-01Us
US6245766 No1998-12-182018-12-18Us
US6399777 No1997-04-012017-04-01Us
US7175855 No2000-05-182020-05-18Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point>300 °CNot Available
logP3.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00718 mg/mLALOGPS
logP4.64ALOGPS
logP4.3ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)13.18ChemAxon
pKa (Strongest Basic)7.09ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area48.47 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity116.72 m3·mol-1ChemAxon
Polarizability44.96 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentN-arylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • Phenethylamine
  • Dihydroindole
  • Indole or derivatives
  • 1,2-benzothiazole
  • Dialkylarylamine
  • Aralkylamine
  • N-alkylpiperazine
  • Chlorobenzene
  • Imidolactam
  • Benzenoid
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Thiazole
  • Azole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Lactam
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706 ]
  2. Kopecek M, Bares M, Mohr P: Ziprasidone-induced galactorrhea: a case report. Neuro Endocrinol Lett. 2005 Feb;26(1):69-70. [PubMed:15726024 ]
  3. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA 3rd, et al.: Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther. 1995 Oct;275(1):101-13. [PubMed:7562537 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  5. Stahl SM, Shayegan DK: The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64 Suppl 19:6-12. [PubMed:14728084 ]
  6. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Mansbach RS, Carver J, Zorn SH: Blockade of drug-induced deficits in prepulse inhibition of acoustic startle by ziprasidone. Pharmacol Biochem Behav. 2001 Jul-Aug;69(3-4):535-42. [PubMed:11509214 ]
  2. Ichikawa J, Li Z, Dai J, Meltzer HY: Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res. 2002 Nov 29;956(2):349-57. [PubMed:12445705 ]
  3. Lu BY, Lundgren R, Escalona PR, Roberts BB: A case of ziprasidone-induced mania and the role of 5-HT2A in mood changes induced by atypical antipsychotics. J Clin Psychiatry. 2002 Dec;63(12):1185-6. [PubMed:12530423 ]
  4. Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, Remington G: A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry. 2004 May;161(5):818-25. [PubMed:15121646 ]
  5. Kast RE, Focosi D, Petrini M, Altschuler EL: Treatment schedules for 5-HT2A blocking in progressive multifocal leukoencephalopathy using risperidone or ziprasidone. Bone Marrow Transplant. 2007 Jun;39(12):811-2. Epub 2007 Apr 23. [PubMed:17450180 ]
  6. Stahl SM, Shayegan DK: The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64 Suppl 19:6-12. [PubMed:14728084 ]
  7. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD5
Uniprot ID:
P21918
Molecular Weight:
52950.5 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Sprouse JS, Reynolds LS, Braselton JP, Rollema H, Zorn SH: Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation. Neuropsychopharmacology. 1999 Nov;21(5):622-31. [PubMed:10516958 ]
  2. Rollema H, Lu Y, Schmidt AW, Sprouse JS, Zorn SH: 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry. 2000 Aug 1;48(3):229-37. [PubMed:10924666 ]
  3. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  4. Wilner KD, Anziano RJ, Johnson AC, Miceli JJ, Fricke JR, Titus CK: The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery. J Clin Psychopharmacol. 2002 Apr;22(2):206-10. [PubMed:11910268 ]
  5. Newman-Tancredi A, Rivet JM, Cussac D, Touzard M, Chaput C, Marini L, Millan MJ: Comparison of hippocampal G protein activation by 5-HT(1A) receptor agonists and the atypical antipsychotics clozapine and S16924. Naunyn Schmiedebergs Arch Pharmacol. 2003 Sep;368(3):188-99. Epub 2003 Aug 16. [PubMed:12923612 ]
  6. Stahl SM, Shayegan DK: The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64 Suppl 19:6-12. [PubMed:14728084 ]
  7. Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH: Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001 Aug 17;425(3):197-201. [PubMed:11513838 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate c...
Gene Name:
HTR1D
Uniprot ID:
P28221
Molecular Weight:
41906.38 Da
References
  1. Stahl SM, Shayegan DK: The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64 Suppl 19:6-12. [PubMed:14728084 ]
  2. Wilner KD, Anziano RJ, Johnson AC, Miceli JJ, Fricke JR, Titus CK: The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery. J Clin Psychopharmacol. 2002 Apr;22(2):206-10. [PubMed:11910268 ]
  3. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA 3rd, et al.: Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther. 1995 Oct;275(1):101-13. [PubMed:7562537 ]
  4. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  5. Sprouse JS, Reynolds LS, Braselton JP, Rollema H, Zorn SH: Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation. Neuropsychopharmacology. 1999 Nov;21(5):622-31. [PubMed:10516958 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.
Gene Name:
HTR1E
Uniprot ID:
P28566
Molecular Weight:
41681.57 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Stahl SM, Shayegan DK: The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64 Suppl 19:6-12. [PubMed:14728084 ]
  2. Sanchez C, Arnt J: In-vivo assessment of 5-HT2A and 5-HT2C antagonistic properties of newer antipsychotics. Behav Pharmacol. 2000 Jun;11(3-4):291-8. [PubMed:11103883 ]
  3. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA 3rd, et al.: Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther. 1995 Oct;275(1):101-13. [PubMed:7562537 ]
  4. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  5. Wood MD, Scott C, Clarke K, Cato KJ, Patel N, Heath J, Worby A, Gordon L, Campbell L, Riley G, Davies CH, Gribble A, Jones DN: Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade. CNS Neurol Disord Drug Targets. 2006 Aug;5(4):445-52. [PubMed:16918396 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Voltage-gated potassium channel activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.
Gene Name:
HTR3A
Uniprot ID:
P46098
Molecular Weight:
55279.835 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs (By similarity). Controls pyramidal neurons migration during corticogenesis, through...
Gene Name:
HTR6
Uniprot ID:
P50406
Molecular Weight:
46953.625 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. Stark AD, Jordan S, Allers KA, Bertekap RL, Chen R, Mistry Kannan T, Molski TF, Yocca FD, Sharp T, Kikuchi T, Burris KD: Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology (Berl). 2007 Feb;190(3):373-82. Epub 2006 Nov 25. [PubMed:17242925 ]
  2. Meltzer HY: The role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 1999 Aug;21(2 Suppl):106S-115S. [PubMed:10432496 ]
  3. Meltzer HY: Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci. 1995;3(2):64-75. [PubMed:7583621 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  2. Arnt J: Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. Eur J Pharmacol. 1995 Sep 5;283(1-3):55-62. [PubMed:7498321 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Andersohn F, Schmedt N, Weinmann S, Willich SN, Garbe E: Priapism associated with antipsychotics: role of alpha1 adrenoceptor affinity. J Clin Psychopharmacol. 2010 Feb;30(1):68-71. doi: 10.1097/JCP.0b013e3181c8273d. [PubMed:20075651 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Prakash C, Kamel A, Cui D, Whalen RD, Miceli JJ, Tweedie D: Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol. 2000;49 Suppl 1:35S-42S. [PubMed:10771452 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Nakamura H, Nakasa H, Ishii I, Ariyoshi N, Igarashi T, Ohmori S, Kitada M: Effects of endogenous steroids on CYP3A4-mediated drug metabolism by human liver microsomes. Drug Metab Dispos. 2002 May;30(5):534-40. [PubMed:11950784 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 02, 2016 02:42